Abstract: The present invention relates to a compound, a pharmaceutical composition comprising the compound, the method for the preparation thereof, and the use thereof as TRK inhibitors. The compound is a compound as shown in the following formula I, and isomers, prodrugs, solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof. The present invention also relates to use of the compound in treating or preventing diseases mediated by TRK, such as cancers, and method for treating such diseases using the compounds of the present invention.

Abstract: The present invention relates to a compound, a pharmaceutical composition containing thereof, preparation methods therefor, and use thereof as BCL-2 inhibitors. The compound is a compound represented by formula (I), or an isomer, prodrug, solvate, stable isotopic derivative or pharmaceutically acceptable salt thereof. The invention also relates to use of the compound for treating or preventing diseases mediated by BCL-2, such as tumors, and to a method for using the same for treating described diseases.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a mitogen-activated protein kinase interacting kinase 1 and 2(MNK1/MNK2) inhibitor. The present invention further relates to a method of treating or prevent MNK-mediated diseases, such as cancer. The compound is a heterocyclic compound as shown in Formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.

Abstract: A security fingerprint architecture is disclosed. A security fingerprint comprises one or more behavioral factors which store a history of events associated with one or more users. The data in the security fingerprint is exposed by one or more modes, each of which determines the conditions that data in the security fingerprint may be accessed. Security fingerprints support a number of primitive operations that allow set operations to be performed. Security fingerprints may be used in for authentication, advertising, and other operations either alone, or in conjunction with third party data sources. An exemplary platform of security fingerprints built upon a cellular infrastructure is also disclosed.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a compound, a pharmaceutical composition comprising the compound, the method for the preparation thereof, and the use thereof as TRK inhibitors. The compound is a compound as shown in the following formula I, and isomers, prodrugs, solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof. The present invention also relates to use of the compound in treating or preventing diseases mediated by TRK, such as cancers, and method for treating such diseases using the compounds of the present invention.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof. The present invention further relates to a method of treating or preventing a FGFR-mediated disease, such as cancer, using the compound.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof. The present invention further relates to a method of treating or preventing a FGFR-mediated disease, such as cancer, using the compound.

Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.

Abstract: Techniques determining a categorized location of a user of a user device based at least in part on a set of location and time pairs for the user device are described herein. The set of location and time pairs for the user device include at least one location and time pair that is associated with a communication of the user device over a communication network. In some embodiments, the techniques further predict a location for the user given a specified time and based at least in part on the set of location and time pairs for the user device.

Abstract: A security fingerprint architecture is disclosed. A security fingerprint comprises one or more behavioral factors which store a history of events associated with one or more users. The data in the security fingerprint is exposed by one or more modes, each of which determines the conditions that data in the security fingerprint may be accessed. Security fingerprints support a number of primitive operations that allow set operations to be performed. Security fingerprints may be used in for authentication, advertising, and other operations either alone, or in conjunction with third party data sources. An exemplary platform of security fingerprints built upon a cellular infrastructure is also disclosed.

Abstract: A security fingerprint architecture is disclosed. A security fingerprint comprises one or more behavioral factors which store a history of events associated with one or more users. The data in the security fingerprint is exposed by one or more modes, each of which determines the conditions that data in the security fingerprint may be accessed. Security fingerprints support a number of primitive operations that allow set operations to be performed. Security fingerprints may be used in for authentication, advertising, and other operations either alone, or in conjunction with third party data sources. An exemplary platform of security fingerprints built upon a cellular infrastructure is also disclosed.

Abstract: Techniques determining a categorized location of a user of a user device based at least in part on a set of location and time pairs for the user device are described herein. The set of location and time pairs for the user device include at least one location and time pair that is associated with a communication of the user device over a communication network. In some embodiments, the techniques further predict a location for the user given a specified time and based at least in part on the set of location and time pairs for the user device.

Abstract: Techniques determining a categorized location of a user of a user device based at least in part on a set of location and time pairs for the user device are described herein. The set of location and time pairs for the user device include at least one location and time pair that is associated with a communication of the user device over a communication network. In some embodiments, the techniques further predict a location for the user given a specified time and based at least in part on the set of location and time pairs for the user device.